Quarterly report pursuant to Section 13 or 15(d)

Collaboration and Research Arrangements - Additional Information (Details)

v3.24.3
Collaboration and Research Arrangements - Additional Information (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenue recognized   $ 3,762,000   $ 9,550,000
Global Blood Therapeutics | Collaboration Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenue recognized $ 0 $ 3,800,000 $ 0 $ 9,600,000